Deals, Partnering

Collaborative R&D agreement to develop personalized oncology drugs using TumorGraft technology platform

Posted on 12 September 2013

Tags: , ,

Champions Oncology and Teva Sign a Discovery and Drug Development Partnership

HACKENSACK, N.J., Sept. 12, 2013 -- Champions Oncology Inc. (OTC:CSBR) ("Champions"), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft™ technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.

This partnership, using the Champions TumorGraft™ technology platform, aims to identify highly responsive cancer subtypes, and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapeutic agents, hopefully leading to new and personalized therapeutic options for patients with cancer. The development process will include initial screening studies on large numbers of TumorGraft models to develop response hypotheses for different tumor types and sub-populations. These hypotheses will be further refined and validated with more in depth studies.

Under the terms of the agreement, Teva will pay Champions an upfront fee and Champions may also receive milestone payments and royalties for the compounds being studied if the response hypotheses are successfully utilized for clinical trial design and resulting commercial success of the compounds.

Joel Ackerman, CEO of Champions commented, "We are excited to announce this opportunity for us to work with the team at Teva to identify and validate sub-populations that are best suited for these compounds. This represents an exciting opportunity for us to align our success with the value our technology provides our customers."

Daily news stories                                                                           

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with TEVA

Report: Biomarker Partnering Terms and Agreements

Report: Diagnostics Partnering Terms and Agreements

View:Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now      Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
a1banner300x150animgif